Navigation Links
Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
Date:6/25/2008

EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that the National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and Lixte Biotechnology Holdings, Inc. extended their Cooperative Research and Development Agreement (CRADA) to develop drugs for the treatment of brain cancers. The CRADA, initiated in March 2006 was extended through September 2009.

Dr. John S. Kovach, President and CEO of Lixte, said, "The scientific interaction with the research team at the Molecular Pathogenesis Unit (MPU), Surgical Neurology Branch, (SNB), NINDS, has been highly productive and is a good example of how government and private sector scientific organizations may accelerate the drug development process. A novel biomarker of glioblastoma multiforme, the most common and aggressive brain tumor of adults, discovered at the MPU, SNB led to insights into potential vulnerability of this devastating cancer to pharmacologic attack. Based on these insights, Lixte synthesized two different types of anti-cancer drugs that target the biomarker. In less than two years, working with the MPU, SNB under the CRADA, Lixte has identified lead compounds of both types, which inhibit glioblastoma multiforme in animal models. These novel compounds are now undergoing pre- clinical evaluation of their pharmacologic characteristics, the first step in the process of preparing an Investigational Drug Application (IND) to the FDA for clinical evaluation."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):

NINDS '/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
4. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
5. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
6. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
7. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
8. Leading Biotechnology Company Grows with StayinFront CRM
9. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
10. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
11. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , , PASADENA, Calif., July ... ), Landlord of Choice to the Life Science Industry(R), announced today ... Lilly and Company as the anchor tenant at the Alexandria Center ... Center"). Lilly has leased approximately 91,000 rentable square feet, as ...
... BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... in China, today announced that it has,initiated dosing today in ... A (H1N1). Results are expected in September,2009. , ... split viron,vaccine with adjuvant, and whole viron vaccine with adjuvant, ...
... , CHICAGO, July 22 Research presented at ... indicates that monitoring cardiac transplant patients with the Urine NGAL ... monitor cyclosporine-induced toxicity and adjust doses of cyclosporine drugs to ... , In a scientific poster presented at ...
Cached Biology Technology:Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 2Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 3Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 4Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) 2Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2
(Date:4/17/2014)... 2014The development of stem cell therapies to cure a ... stem cell populations based on cell surface markers. Researchers ... marker that is highly expressed in a type of ... they describe in an article in BioResearch Open ... Inc., publishers. The article is available free on the ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia National ... testing safer, easier, faster and cheaper. , ... commonly found in soils all over the world and ... humans and animals. The bacteria can survive in harsh ... anthracis may occur through skin contact, inhalation of ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... German . , Wounds suffered by ... to work, the patient,s physician must discuss the situation ... best approach. However, e-mailing the files containing the diagnosis ... process. Telemedicine could facilitate communication and provide a better ...
... Matthew Levy, Ph.D., assistant professor of biochemistry at Albert ... awarded more than $700,000 by Stand Up To Cancer ... will focus on creating self-guiding drugs that target only ... unpleasant side effects of current therapies. Dr. Levy is ...
... exhaustive research into venom produced by snakes and spiders, ... a mystery. Now, a study of 158 catfish species, ... Biology , has catalogued the presence of venom glands ... Wright, from the University of Michigan, USA, carried out ...
Cached Biology News:A virtual physician's conference 2Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3
... net results - with a modular approach ... management! The ChemStation Plus NDS family provides ... acquisition and data management, giving you the ... your labs needs now and that can ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... for immunological studies, vaccine development, and ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive Epitope Peptide ... Content Probe content is completely ...
... These extended-length microarrays are custom designed ... format configurations are available: 8,455 features per ... or 22,575 features per array (1 array/slide). ... oligonucleotide probe length - This extended ...
Biology Products: